scholarly journals Metastatic Colon Cancer from Lung Cancer which Demonstrated Rapid and Aggressive Growth: A Case Report

2008 ◽  
Vol 61 (7) ◽  
pp. 410-414 ◽  
Author(s):  
Hiroki Akamatsu ◽  
Nobuo Ogino
Keyword(s):  
Lung Cancer ◽  
Colon Cancer ◽  
Case Report ◽  
Metastatic Colon Cancer

A case of aseptic meningitis in a cetuximab-experienced patient with metastatic colon cancer

2017 ◽  
Vol 24 (8) ◽  
pp. 632-633 ◽  
Author(s):  
Chelsea L Rohrer ◽  
Zunilda Grullon ◽  
Sarah K George ◽  
Raul Castillo ◽  
Kelli Karasiewicz
Keyword(s):  
Colorectal Cancer ◽  
Lung Cancer ◽  
Colon Cancer ◽  
Case Report ◽  
Aseptic Meningitis ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Metastatic Colon Cancer ◽  
Small Cell Lung ◽  
Epidermal Growth

Cetuximab is a monoclonal antibody against epidermal growth factor receptor and is used in the treatment of head and neck cancer, non-small cell lung cancer, and colorectal cancer. This case report describes a rare (<1% incidence) side effect of cetuximab administration: aseptic meningitis. We report a case which is, to our knowledge, the only case at the time of submission of this manuscript of aseptic meningitis in a patient being treated for metastatic colon cancer who was not cetuximab-naïve. This case report may help inform clinicians about the identification and outcome of this adverse event.

scholarly journals Metastatic colon cancer in the pituitary: A case report with review of literature

2021 ◽  
Vol 16 (4) ◽  
pp. 872
Author(s):  
Kishan Karia ◽  
Sally-Ann Price ◽  
WaiCheong Soon ◽  
YasirArafat Chowdhury ◽  
KyawZayar Thant ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Case Report ◽  
Metastatic Colon Cancer ◽  
Review Of Literature

scholarly journals Pancreatic cystic desmoid tumor following metastatic colon cancer surgery: A case report

2020 ◽  
Vol 15 (11) ◽  
pp. 2063-2066
Author(s):  
Shahab Shayesteh ◽  
Kevan J. Salimian ◽  
Daniel Fadaei Fouladi ◽  
Alejandra Blanco ◽  
Linda C. Chu ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Case Report ◽  
Desmoid Tumor ◽  
Cancer Surgery ◽  
Metastatic Colon Cancer ◽  
Colon Cancer Surgery

Delay in time from diagnosis to treatment in metastatic melanoma, lung, and colon cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e23186-e23186
Author(s):  
Muhammad Salman Faisal ◽  
Ahmed Khattab ◽  
Vida Jahangiri ◽  
Hira Shaikh ◽  
Soorih Shaikh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Colon Cancer ◽  
Demographic Data ◽  
Tertiary Care ◽  
The United States ◽  
Definitive Treatment ◽  
Metastatic Colon Cancer ◽  
Female Ratio ◽  
Number Of Patients ◽  
Delay In Treatment

e23186 Background: Delay in cancer treatment is anxiety provoking both for the patient and clinician. We conducted the study to evaluate the patterns of delay in treatment of patients with metastatic colon cancer, lung cancer and melanoma from diagnosis to the initiation of the treatment, and to identify the causes of delay. Methods: In this retrospective study, patients with metastatic colon cancer, lung cancer and melanoma diagnosed between 01/01/2016 to 12/31/2016 in a tertiary care network in the United States were studied. Data was collected from electronic health record (EHR) database, ‘Epic’. Variables such as demographic data, including patient age and gender, and type of cancer, and treatment received were analyzed. The causes of the delay were also evaluated when available. Results: Total number of patients in the study was 288. Mean age was 68.3 years (median 69 years) and 36% were alive at the time of data analysis. Male to female ratio was 1.4:1. 66.7% people had lung cancer, 30% had colon cancer and 3% had melanoma. 67 (23.6%) of total analyzed patients had denied definitive treatment and chose to undergo palliative management. Of the rest, most started treatment with chemotherapy (39.5%), followed by surgery (22.6%) and then radiation (14.6%). With the time of pathological diagnosis of the tumor taken as the date of diagnosis, mean delay from the day of diagnosis to the start of treatment in this study population observed was 27.7 days. 67 patients (23.3%) had a delay of more than 30 days, with the most common reason being systemic factors in 39 patients (58.2%), followed by patient factors in 23 patients (34.3%) and physician factors in 5 patients (7.5%). On logistic regression analysis, time from diagnosis to treatment didn’t predict mortality (OR = 0.99, 95% CI P = 0.10(0.97-1.002). Conclusions: Delay in treatment is common and the system factors one of the common reasons as exhibited by our study. Time from diagnosis to treatment didn’t predict mortality.

scholarly journals Cancer-related multiple brain infarctions caused by Trousseau syndrome in a patient with metastatic colon cancer: a case report

2016 ◽  
Vol 2 (1) ◽  
Author(s):  
Takahiko Akiyama ◽  
Yuji Miyamoto ◽  
Yasuo Sakamoto ◽  
Ryuma Tokunaga ◽  
Keisuke Kosumi ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Case Report ◽  
Metastatic Colon Cancer ◽  
Trousseau Syndrome

scholarly journals Complete response of MSI‑high metastatic colon cancer following treatment with regorafenib: A case report

2021 ◽  
Vol 15 (5) ◽  
Author(s):  
Hyungjoo Baik ◽  
Hee Lee ◽  
Jueun Park ◽  
Ha Park ◽  
Jinyoung Park ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Case Report ◽  
Complete Response ◽  
Metastatic Colon Cancer

Comparison of BEAMing assays and competitive approaches in the detection of main alteration of RAS in circulating DNA of non small-cell lung cancer (NSCLC) and metastatic colon cancer. Manuscript 2016.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e23056-e23056
Author(s):  
Jessica Garcia ◽  
Julien Forestier ◽  
Eric Dusserre ◽  
Claire Rodriguez-Lafrasse ◽  
Valérie Cheynet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Colon Cancer ◽  
Tumor Progression ◽  
Detection Threshold ◽  
Metastatic Colon Cancer ◽  
Plasma Dna ◽  
Liquid Biopsies ◽  
Mutational Status ◽  
Somatic Alterations ◽  
High Level

e23056 Background: A number of RAS mutations confer resistance to anti-EGFR therapies routinely used in the treatment of colon cancer. The objective of this study was to evaluate the pertinence of analyzing circulating-free plasma DNA (cfDNA) as an indicator of the mutational status of a tumor, in order to use liquid biopsies instead of invasive and painful tumor biopsies during tumor progression. Methods: A cohort of 24 lung and 25 colon cancer patients was constituted in the Hospices Civils of Lyon. Liquid biopsy plasma samples were collected at diagnosis (colon cancer) and during tumor progression (lung cancer) for the purpose of the current study. KRAS and NRAS somatic alterations were quantified using three different technologies: the Droplet Digital polymerase chain reaction (ddPCR) from BioRad, the BEAMing Digital PCR from Sysmex Inostics, and the NGS NextSeq 500 by Illumina with the Accel-Amplicon 56G Oncology Panel from SWIFT BIOSCIENCES. Results: We observed a high level of sensitivity and specificity with the BEAMing technology, which provided us with excellent matches, around 96% and 73%, between solid and liquid biopsies taken at diagnosis (colon cancer) or during tumor progression (lung cancer), respectively. Indeed, when examining cfDNA from patients displaying one of the KRAS or NRAS mutations, 11 of the 13 mutations were confirmed using this technology, whereas only 5-6 matched the initial NGS status, using the two other technologies. The detection threshold was estimated at 1% for samples containing at least 0.8 ngctDNA/µL for the multiplex screening ddPCR from BioRad and for the 56G Oncology Panel from SWIFT BIOSCIENCES. The threshold was lower, at 0.03%, in samples containing only 0.25 ng ctDNA/µL for the BEAMing technology, which includes a PCR pre-amplification step. Conclusions: The advantage of the Illumina NGS technology is the larger coverage of longer gene regions, and thus the detection of more genetic mutations. Finally, the BEAMing technology enabled us to follow the appearance and disappearance of somatic alterations, with a very high level of sensitivity.

scholarly journals A case report on efficacy of Abound™ for anti-EGFR antibody-associated skin disorder in metastatic colon cancer

2014 ◽  
Vol 12 (1) ◽  
pp. 35 ◽  
Author(s):  
Nobuhisa Matsuhashi ◽  
Takao Takahashi ◽  
Kenichi Nonaka ◽  
Kengo Ichikawa ◽  
Kazunori Yawata ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Case Report ◽  
Skin Disorder ◽  
Metastatic Colon Cancer ◽  
Egfr Antibody
Sign in / Sign up

Export Citation Format

Share Document